Showing results (151-160 of 245) with videos related to

Sort By:
Pageof 25
Acta Oncologica (Stockholm, Sweden)|July 20, 2021
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapyRoberto Filippi, Francesco Montagnani, Pasquale Lombardi, et al.
Critical Reviews in Oncology/Hematology|March 6, 2017
Multimodal treatment of resectable pancreatic ductal adenocarcinomaNicola Silvestris, Oronzo Brunetti, Enrico Vasile, et al.
Cancers|July 24, 2021
Drug Holidays and Overall Survival of Patients with Metastatic Colorectal CancerSilvio Ken Garattini, Debora Basile, Marta Bonotto, et al.
Scientific Reports|April 28, 2016
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patientsRiccardo Giampieri, Lisa Salvatore, Michela Del Prete, et al.
Translational Lung Cancer Research|February 11, 2021
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcomeAlberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, et al.
Plos One|July 18, 2013
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabFotios Loupakis, Chiara Cremolini, Dongyun Yang, et al.
International Journal of Cancer|June 12, 2020
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancerCindy Neuzillet, Andrea Casadei-Gardini, Bertrand Brieau, et al.
British Journal of Cancer|November 18, 2015
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancerFotios Loupakis, Roberto Moretto, Giuseppe Aprile, et al.
Clinical Nutrition (Edinburgh, Scotland)|June 18, 2020
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot studyDebora Basile, Michele Bartoletti, Maurizio Polano, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2021
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 studyRoberto Moretto, Mirella Giordano, Anello M Poma, et al.
Pageof 25